Evaluating advanced glycation end products by the clinical effects of Astragali Radix using skin autofluorescence

Abstract

Advanced glycation end products (AGEs) associated with diabetes, renal failure, and non‐alcoholic fatty liver disease have recently been receiving attention. The present study aimed to investigate therapeutic effects of Astragali Radix (AR) using skin autofluorescence (SAF) to evaluate AGEs. Treatment group (May 2019 to May 2020) was 18 patients. AR administration period was six months. SAF, body mass index, mean blood pressure, hemoglobin A1c, serum creatinine, estimated glomerular filtration rate (eGFR), aspartate transaminase, and alanine transaminase (ALT) were used.